The global allergy immunotherapy market size is expected to be valued at US$ 3.6 billion in 2026 and projected to reach US$ 6.3 billion growing at a CAGR of 8.2% between 2026 and 2033. Rising global prevalence of allergic diseases is the primary force behind this rapid expansion.

The World Health Organization estimates that allergic conditions affect a substantial and growing share of the global population, with allergic rhinitis and asthma among the most commonly diagnosed chronic conditions. Growing physician and patient preference for disease-modifying immunotherapy over symptomatic treatment alone, combined with expanding product approvals, continues to drive robust demand for allergy immunotherapy worldwide.

Drivers - Rising Global Prevalence of Allergic Rhinitis and Asthma Strengthens Demand

The rising global prevalence of allergic rhinitis and asthma is significantly strengthening demand for allergy immunotherapy treatments. The World Health Organization estimates that allergic conditions rank among the most common chronic diseases worldwide, with prevalence rates continuing to climb across both developed and emerging economies due to rising urban pollution and allergen exposure. Growing clinical recognition of immunotherapy as the only treatment approach capable of modifying the underlying allergic disease process, rather than merely masking symptoms, continues to drive physician recommendation rates higher.

Allergy specialists increasingly recommend immunotherapy for patients with moderate to severe symptoms poorly controlled by conventional antihistamines or corticosteroids. As global allergy diagnosis rates continue rising, driven by improved screening and public health awareness campaigns, demand for both subcutaneous and sublingual immunotherapy formulations is expected to see sustained growth throughout the forecast period.

Growing Regulatory Approvals for Sublingual Immunotherapy Formulations

The growing number of regulatory approvals for sublingual immunotherapy formulations is significantly expanding treatment accessibility across major markets. Regulatory bodies such as the U.S. Food and Drug Administration have approved several sublingual tablet formulations in recent years, allowing patients to self-administer treatment at home rather than requiring frequent clinic visits for injection-based therapy. This regulatory expansion improves patient convenience and treatment adherence, factors that have historically limited immunotherapy completion rates given the multi-year treatment duration typically required.

Companies such as ALK-Abelló A/S and Stallergenes Greer continue to expand their sublingual product portfolios to capture this growing demand. As more countries approve sublingual immunotherapy formulations for grass, tree, and dust mite allergies, this treatment format is expected to see accelerated adoption across both pediatric and adult patient populations worldwide.

Restraints - Long Treatment Duration Reduces Patient Adherence

The extended treatment duration required for allergy immunotherapy, typically spanning three to five years, presents a notable restraint affecting patient adherence rates. Clinical research continues to document declining patient compliance over the course of long-term immunotherapy regimens, with many patients discontinuing treatment before completing the full recommended course. This extended commitment can discourage patients from initiating therapy in the first place, particularly among those seeking faster symptom relief.

Physicians must invest additional time in patient education and adherence counseling to improve completion rates, adding to the overall cost and complexity of delivering effective immunotherapy treatment.

Risk of Allergic Reactions Limits Broader Adoption

The inherent risk of allergic reactions, including rare cases of anaphylaxis, associated with allergen exposure during immunotherapy treatment continues to restrain broader market adoption. Regulatory bodies require specific safety monitoring protocols, particularly for subcutaneous immunotherapy administered via injection, requiring patients to remain under clinical observation following each dose. This safety requirement limits treatment convenience and increases the burden on healthcare facilities offering immunotherapy services.

Some patients and physicians remain cautious about initiating treatment due to these safety considerations, particularly for high-risk patient populations with severe underlying asthma or other complicating health conditions.

Opportunities - Growing Adoption of Sublingual Immunotherapy Creates a Strong Growth Window

The rising adoption of sublingual immunotherapy presents a significant growth opportunity for manufacturers positioned to expand this treatment format. Sublingual formulations offer patients the convenience of at-home self-administration, eliminating the need for frequent clinic visits required by traditional subcutaneous injection therapy. Growing physician confidence in sublingual efficacy data, supported by expanding clinical trial evidence, continues to drive increased prescribing rates across allergy and immunology practices.

Companies such as HAL Allergy B.V. and LETI Pharma continue to expand their sublingual immunotherapy research and development pipelines to capture this growing demand. As patient preference for convenient, self-administered treatment options continues to strengthen, particularly among working adults and pediatric patients, sublingual immunotherapy adoption is expected to accelerate significantly, offering manufacturers a valuable avenue for portfolio expansion and improved treatment completion rates.

Expanding Pediatric Allergy Treatment Access Opens New Avenues

Rising diagnosis rates of allergic conditions among children present a valuable growth opportunity for allergy immunotherapy manufacturers. Pediatric allergists increasingly recommend early immunotherapy intervention to prevent disease progression from allergic rhinitis to allergic asthma, a phenomenon well documented in allergy research literature. Growing pediatric-specific product development, including age-appropriate sublingual tablet formulations, continues to expand treatment accessibility for younger patient populations.

Companies such as Allergy Therapeutics plc continue to invest in pediatric-focused immunotherapy research and formulation development. As awareness of early intervention benefits continues to spread through pediatric allergy and immunology associations, manufacturers developing pediatric-specific immunotherapy products stand to capture meaningful new demand from this expanding and historically underserved patient segment.

Treatment Type Insights

Subcutaneous Immunotherapy (SCIT) held the leading position within the treatment type category, accounting for an estimated 63% share of the market in 2026. Its dominance stems from decades of established clinical use, broad allergen coverage capability, and strong physician familiarity with injection-based administration protocols.

SCIT allows physicians to treat multiple allergen sensitivities simultaneously through customized allergen extract formulations, a flexibility not always available with standardized sublingual tablet products. Extensive clinical evidence supporting its long-term efficacy across multiple allergy types continues to reinforce physician confidence in this treatment approach. Meanwhile, Sublingual Immunotherapy (SLIT) represents the fastest-growing treatment type segment, driven by rising patient preference for convenient, at-home self-administration and growing regulatory approvals for standardized sublingual tablet formulations, a trend expected to accelerate as more allergen-specific products reach the market.

Allergy Type Insights

Allergic Rhinitis (Hay Fever) held the leading position within the allergy type category, supported by its status as the most commonly diagnosed allergic condition treated with immunotherapy worldwide. Rising pollen exposure, urban air pollution, and growing awareness of allergy symptom management continue to drive high treatment-seeking rates among affected patients. Physicians frequently recommend immunotherapy as a disease-modifying treatment option for patients with moderate to severe seasonal or perennial allergic rhinitis symptoms poorly controlled by conventional medications.

Allergic asthma represents the fastest-growing allergy type segment, propelled by rising global asthma prevalence and growing clinical evidence supporting immunotherapy's role in reducing asthma exacerbations linked to underlying allergen sensitivities, a trend expected to continue accelerating as awareness of this treatment application grows among pulmonologists and allergists.

North America Allergy Immunotherapy Market

North America dominated the global allergy immunotherapy market and accounted for the largest revenue share in 2026, supported by a high prevalence of allergic diseases, strong reimbursement systems, and widespread adoption of disease-modifying allergy treatments. According to the U.S. Centers for Disease Control and Prevention (CDC), nearly 25.7% of U.S. adults and 18.9% of children experienced seasonal allergies in 2021, while asthma affected around 25 million Americans, creating sustained demand for allergen immunotherapy.

Canada has also reported a steady increase in allergic conditions, with Asthma Canada estimating that more than 3.8 million Canadians live with asthma. The regional growth benefits from well-established allergy specialist networks, availability of FDA- and Health Canada-approved immunotherapy products, and continuous clinical research. Rising awareness of long-term disease modification over symptomatic treatment continues to support market expansion.

U.S. Allergy Immunotherapy Market Trends

The U.S. remained the largest contributor to the North American allergy immunotherapy market and is expected to reach approximately US$ 1.12 billion by 2026. According to the CDC, 25.7% of adults and 18.9% of children suffered from seasonal allergies in 2021. The Asthma and Allergy Foundation of America (AAFA) estimates that over 100 million Americans experience various allergies annually, while approximately 28 million people have asthma. Increasing physician preference for sublingual and subcutaneous immunotherapy, expanding FDA approvals for allergy tablets, and strong insurance coverage continue to support adoption.

Extensive clinical research activities and the presence of major manufacturers such as ALK-Abelló, Stallergenes Greer, and HollisterStier Allergy further reinforce the country's leadership in allergy immunotherapy.

Canada Allergy Immunotherapy Market

Canada is projected to be the fastest-growing market in North America and is expected to grow at a CAGR of 8.8% in the years ahead. Asthma Canada estimates that more than 3.8 million Canadians live with asthma, while seasonal allergic rhinitis affects millions of Canadians every year. Increasing environmental allergen exposure, longer pollen seasons associated with climate change, and growing referrals to allergy specialists are expanding demand for immunotherapy.

Health Canada has continued to approve advanced allergy immunotherapy products, while healthcare providers are increasingly recommending immunotherapy as a long-term disease-modifying treatment. Rising patient awareness and expanding access to allergy clinics are expected to accelerate adoption throughout the forecast period.

Europe Allergy Immunotherapy Market

Europe represented the second-largest regional market owing to its long history of allergen immunotherapy adoption, favorable reimbursement policies, and strong presence of leading manufacturers. According to the European Academy of Allergy and Clinical Immunology (EAACI), more than 150 million Europeans currently live with chronic allergic diseases, and the number could exceed half of Europe's population by 2050 if current trends continue. Allergic rhinitis affects between 20% and 30% of the European population, creating a substantial patient pool for immunotherapy.

Europe also benefits from mature clinical guidelines supporting allergy immunotherapy as a disease-modifying treatment. Countries including Germany, France, Italy, and Spain maintain extensive allergy specialist networks and high awareness among physicians. Continued innovation in sublingual immunotherapy tablets and strong clinical evidence supporting long-term efficacy continue to drive regional growth.

Germany Allergy Immunotherapy Market

Germany led the European allergy immunotherapy market and is expected to reach approximately US$ 0.39 billion by 2026. Germany has one of Europe's most developed allergy care systems and hosts leading manufacturers including ALK-Abelló Germany, Stallergenes Greer Germany, and Allergopharma. According to the Robert Koch Institute, allergic diseases remain among the country's most common chronic conditions, with allergic rhinitis affecting a significant proportion of adults.

Strong reimbursement, well-established allergy centers, and high physician adherence to EAACI treatment guidelines continue to support immunotherapy utilization. Ongoing research collaborations and increasing adoption of sublingual allergy tablets further strengthen Germany's leadership in Europe.

France Allergy Immunotherapy Market

France is expected to be the fastest-growing allergy immunotherapy market in Europe and is projected to expand at a CAGR of 8.6% during 2026–2033. The country has experienced rising allergic rhinitis and asthma prevalence associated with urbanization and environmental changes. France also benefits from strong academic research in allergology and broad access to specialist healthcare services. Increased prescribing of allergen immunotherapy, particularly for pollen and house dust mite allergies, has supported market expansion.

Government-supported healthcare reimbursement, growing patient awareness regarding disease-modifying therapies, and continuous product innovation from domestic and multinational manufacturers are expected to sustain robust growth throughout the forecast period.

Asia Pacific Allergy Immunotherapy Market

Asia Pacific is projected to register the fastest growth in the global allergy immunotherapy market, supported by rapid urbanization, worsening air pollution, increasing pollen exposure, and improving allergy diagnosis rates. The World Allergy Organization estimates that allergic diseases are rising rapidly across Asia, while the World Health Organization identifies air pollution as a major contributor to respiratory allergic disorders.

Countries including China, Japan, South Korea, and India are reporting increasing allergic rhinitis and asthma prevalence, accompanied by expanding healthcare expenditure and specialist allergy services. Regulatory approvals for new immunotherapy products and greater physician awareness are accelerating adoption across the region. Improvements in healthcare infrastructure and increasing availability of sublingual immunotherapy are expected to support strong market growth, making Asia Pacific the fastest-growing regional market over the forecast period.

China Allergy Immunotherapy Market

China accounted for the largest share of the Asia Pacific market and is expected to reach approximately US$ 0.34 billion by 2026. Studies published by the Chinese Society of Allergy indicate that allergic rhinitis affects approximately 17–20% of the Chinese population, with prevalence increasing in major urban areas. Rapid industrialization, air pollution, and changing environmental conditions continue to increase allergic disease burden. China has expanded allergy specialty centers and increased investment in immunotherapy research and clinical practice.

Growing availability of standardized allergen extracts and rising awareness among physicians regarding long-term disease modification are expected to strengthen market demand over the coming years.

India Allergy Immunotherapy Market

India is projected to be the fastest-growing market in Asia Pacific and is expected to grow at a CAGR of 10.8% by 2033. According to the Indian Council of Medical Research (ICMR), allergic respiratory diseases continue to increase across urban and semi-urban populations. The Indian Chest Society estimates that allergic rhinitis affects nearly 20–30% of the population, while asthma affects approximately 35 million people. Increasing air pollution, rapid urbanization, and rising awareness of allergy diagnosis are expanding the eligible patient population.

Growth in allergy specialty clinics, greater availability of immunotherapy products, and increasing physician adoption of evidence-based allergy management are expected to drive strong market expansion throughout the forecast period.

The global allergy immunotherapy market is moderately consolidated, with a group of established specialty pharmaceutical companies accounting for a substantial share of global revenue, alongside a growing number of emerging biotechnology companies developing novel immunotherapy formulations. Leading companies continue to prioritize research and development investment aimed at developing standardized, allergen-specific sublingual tablet formulations offering improved patient convenience.

Strategic partnerships between manufacturers and allergy clinic networks are becoming increasingly common, enabling faster patient access to newer treatment formats. Key differentiators among market leaders include allergen extract standardization, clinical trial evidence depth, and regulatory approval breadth across multiple allergen types and geographic markets.

Key Developments

• June 2026: Stallergenes Greer presented new clinical evidence on the long-term outcomes of allergen immunotherapy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026. The company shared data demonstrating the sustained clinical benefits of allergen immunotherapy, including prolonged symptom control, reduced reliance on allergy medications, and improved quality of life following treatment completion.
• April 2026: ALK-Abelló A/S announced positive results from its Phase 2 clinical trial evaluating its investigational sublingual immunotherapy (SLIT) tablet for peanut allergy. The study demonstrated an early onset of efficacy, with treated participants showing improved tolerance to peanut protein compared to baseline.